NovoCure Ltd.
341 articles about NovoCure Ltd.
-
Novocure Reports First Quarter 2023 Financial Results
5/4/2023
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2023.
-
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
4/26/2023
Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6.
-
Novocure to Report First Quarter 2023 Financial Results
4/3/2023
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets open.
-
Kristin Stafford Joins Novocure Board of Directors
3/29/2023
Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors.
-
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
3/16/2023
Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
-
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
3/1/2023
Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France.
-
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
3/1/2023
Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patients with brain metastases resulting from non-small cell lung cancer (NSCLC).
-
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
2/23/2023
Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
2/23/2023
Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors.
-
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
2/15/2023
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of patients with locally advanced pancreatic cancer.
-
Novocure Announces Organizational Changes to Prepare for Future Growth
1/19/2023
Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17.
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
1/9/2023
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022.
-
NovoCure's novel cancer-fighting platform hits the mark in non-small cell lung cancer.
-
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
1/5/2023
Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone.
-
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
12/27/2022
Novocure announced it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023.
-
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
11/29/2022
Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM).
-
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
11/23/2022
Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022.
-
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
11/17/2022
Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20 in Tampa.
-
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
11/15/2022
Novocure announced it has opened a new office in Montreal to expand and support its growing business in Canada.
-
Novocure Secures CE Mark for New Array
11/11/2022
Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater comfort for patients with glioblastoma.